SCHEDULE: Alkeon Capital Reports 4.6% Stake in Oric Pharma

Alkeon Capital Management LLC and Panayotis D. Sparaggis have filed an Amendment No. 3 to Schedule 13G, reporting beneficial ownership of 4.6% of Oric Pharmaceuticals, Inc.'s common stock as of September 30, 2025.

Summary

• Alkeon Capital Management LLC and Panayotis D. Sparaggis collectively beneficially own 4,504,096 shares of Oric Pharmaceuticals, Inc. common stock.
• This ownership represents 4.6% of the company's outstanding common stock.
• The reporting persons hold shared voting power and shared dispositive power over all 4,504,096 shares.
• The percentage of class is calculated based on 97,122,987 shares of Common Stock outstanding as of August 5, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a neutral regulatory filing disclosing beneficial ownership, with no inherent positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of institutional ownership, indicating Alkeon Capital Management's continued investment in Oric Pharmaceuticals. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.

Key Dates

Keywords

Oric Pharmaceuticals, Alkeon Capital Management, Panayotis D. Sparaggis, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Ownership, Investment Management